title: Effects of liraglutide on no-reflow in patients with acute ST-segment elevation myocardial infarction.
abstract: BACKGROUND
  The 'no-reflow' phenomenon after a percutaneous coronary intervention (PCI) in patients with acute ST-segment elevation myocardial infarction (STEMI) is a strong predictor of both short- and long-term mortality. Glucagon-like peptide-1 (GLP-1) exerts a cardioprotective effect during ischemia reperfusion injury. We planned to evaluate the effects of liraglutide on myocardial no-reflow after PCI for STEMI.
  
  
  METHODS
  A total of 284 patients with STEMI undergoing PCI were enrolled in this study between September 2013 and March 2015. Of these, 210 patients were randomized 1:1 to receive either liraglutide or placebo 30 min before PCI (1.8 mg).
  
  
  RESULTS
  The primary end point, the prevalence of no-reflow, was significantly lower in the liraglutide group than in the control group (5% vs. 15%, P=0.01). Administration of liraglutide was consistently identified as a significant determinant for no-reflow ratio. There was a significant decrease in serum high-sensitivity C-reactive protein levels at 6-hour reperfusion in the liraglutide group compared to the control group (0.87 ± 0.09 mg/dL vs. 0.96 ± 0.10mg/dL, P<0.001). During a 3-month follow-up period, no difference was observed in the incidence of major adverse cardiovascular event.
  
  
  CONCLUSIONS
  Liraglutide may be associated with less no-reflow in STEMI, which should be confirmed by larger-scale trials.
authors: Department of Cardiology, PLA General Hospital, at Beijing, China.
authors: Wei Ren
authors: WR
authors: Chen
authors: Department of Cardiology, PLA General Hospital, at Beijing, China.
authors: Feng
authors: F
authors: Tian
authors: Department of Cardiology, PLA General Hospital, at Beijing, China. Electronic address: cyundai@vip.163.com.
authors: Yun Dai
authors: YD
authors: Chen
authors: Department of Cardiology, PLA General Hospital, at Beijing, China.
authors: Jing
authors: J
authors: Wang
authors: Department of Cardiology, PLA General Hospital, at Beijing, China.
authors: Jun Jie
authors: JJ
authors: Yang
authors: Department of Cardiology, PLA General Hospital, at Beijing, China.
authors: Zhi Feng
authors: ZF
authors: Wang
authors: Department of Cardiology, PLA General Hospital, at Beijing, China.
authors: Jin
authors: J
authors: Da Wang
authors: Department of Cardiology, PLA General Hospital, at Beijing, China.
authors: Qing Xiu
authors: QX
authors: Ning
mesh_terms: D000368:Aged; D005260:Female; D005500:Follow-Up Studies; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D000069450:Liraglutide / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging* / Q000628:therapy*; D054318:No-Reflow Phenomenon / Q000000981:diagnostic imaging* / Q000628:therapy*; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects / Q000639:trends*; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D007004:Hypoglycemic Agents; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1
keywords: Acute ST-segment elevation myocardial infarction; Glucagon-like peptide-1; No-reflow; Percutaneous coronary intervention; Reperfusion injury